Trial Profile
A Phase II, Open-label, Multicentre, Randomised Study of Neoadjuvant and Adjuvant Treatment in Patients With Resectable, Early-stage (II to IIIB) Non-small Cell Lung Cancer (NeoCOAST-2)
Status:
Recruiting
Phase of Trial:
Phase II
Latest Information Update: 03 Jun 2025
Price :
$35
*
At a glance
- Drugs AZD 0171 (Primary) ; Carboplatin (Primary) ; Cisplatin (Primary) ; Datopotamab deruxtecan (Primary) ; Durvalumab (Primary) ; Monalizumab (Primary) ; Oleclumab (Primary) ; Pemetrexed (Primary) ; Rilvegostomig (Primary) ; Volrustomig (Primary)
- Indications Non-small cell lung cancer
- Focus Adverse reactions; Therapeutic Use
- Acronyms NeoCOAST 2
- Sponsors AstraZeneca
Most Recent Events
- 01 Jun 2025 According to a Daiichi Sankyo Company Media Release, data from this study presented at the 2025 American Society of Clinical Oncology (#ASCO25) Annual Meeting and published in Nature Medicine.
- 01 Jun 2025 Results presented in a Daiichi Sankyo Company Media Release.
- 13 May 2025 According to an Innate Pharma media release, an update on the outcomes of the Phase 2 study NeoCOAST-2 will be presented at the upcoming ASCO Annual Meeting in June 2025.